These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24060868)

  • 81. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
    Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
    Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay.
    Lin C; Rice CM
    Proc Natl Acad Sci U S A; 1995 Aug; 92(17):7622-6. PubMed ID: 7644466
    [TBL] [Abstract][Full Text] [Related]  

  • 85. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335.
    Lagacé L; White PW; Bousquet C; Dansereau N; Dô F; Llinas-Brunet M; Marquis M; Massariol MJ; Maurice R; Spickler C; Thibeault D; Triki I; Zhao S; Kukolj G
    Antimicrob Agents Chemother; 2012 Jan; 56(1):569-72. PubMed ID: 22024816
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba.
    Andonov A; Kadkhoda K; Osiowy C; Kaita K
    Can J Gastroenterol; 2013 Jul; 27(7):414-6. PubMed ID: 23862174
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.
    Camus G; Xu S; Han B; Lu J; Dvory-Sobol H; Yu M; Cheng G; Miller MD; Doehle BP; Mo H
    Virology; 2018 Jan; 514():134-141. PubMed ID: 29175627
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death.
    Mateu G; Donis RO; Wakita T; Bukh J; Grakoui A
    Virology; 2008 Jul; 376(2):397-407. PubMed ID: 18455749
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
    Franco S; Clotet B; Martínez MA
    Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
    Yang H; Robinson M; Corsa AC; Peng B; Cheng G; Tian Y; Wang Y; Pakdaman R; Shen M; Qi X; Mo H; Tay C; Krawczyk S; Sheng XC; Kim CU; Yang C; Delaney WE
    Antimicrob Agents Chemother; 2014; 58(2):647-53. PubMed ID: 23939899
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    Fevery B; Verbinnen T; Peeters M; Janssen K; Witek J; Jessner W; De Meyer S; Lenz O
    J Viral Hepat; 2017 Jan; 24(1):28-36. PubMed ID: 27696653
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography.
    Sudo K; Inoue H; Shimizu Y; Yamaji K; Konno K; Shigeta S; Kaneko T; Yokota T; Shimotohno K
    Antiviral Res; 1996 Aug; 32(1):9-18. PubMed ID: 8863991
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.
    Soumana DI; Kurt Yilmaz N; Ali A; Prachanronarong KL; Schiffer CA
    J Am Chem Soc; 2016 Sep; 138(36):11850-9. PubMed ID: 27512818
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships.
    Hu K; Zhu Z; Mathahs MM; Tran H; Bommer J; Testa CA; Schmidt WN
    Drug Des Devel Ther; 2020; 14():757-771. PubMed ID: 32158194
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The acidic domain of the hepatitis C virus NS4A protein is required for viral assembly and envelopment through interactions with the viral E1 glycoprotein.
    Roder AE; Vazquez C; Horner SM
    PLoS Pathog; 2019 Feb; 15(2):e1007163. PubMed ID: 30730994
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
    Ahmed-Belkacem A; Ahnou N; Barbotte L; Wychowski C; Pallier C; Brillet R; Pohl RT; Pawlotsky JM
    Gastroenterology; 2010 Mar; 138(3):1112-22. PubMed ID: 19962982
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.
    Gottwein JM; Scheel TK; Callendret B; Li YP; Eccleston HB; Engle RE; Govindarajan S; Satterfield W; Purcell RH; Walker CM; Bukh J
    J Virol; 2010 May; 84(10):5277-93. PubMed ID: 20200247
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
    Pedersen J; Jensen TB; Carlsen TH; Schønning K; Christensen PB; Laursen AL; Krarup H; Bukh J; Weis N
    PLoS One; 2013; 8(5):e62674. PubMed ID: 23667506
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus.
    Paulson MS; Yang H; Shih IH; Feng JY; Mabery EM; Robinson MF; Zhong W; Delaney WE
    Antiviral Res; 2009 Aug; 83(2):135-42. PubMed ID: 19457562
    [TBL] [Abstract][Full Text] [Related]  

  • 100. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication.
    Lindenbach BD; Prágai BM; Montserret R; Beran RK; Pyle AM; Penin F; Rice CM
    J Virol; 2007 Sep; 81(17):8905-18. PubMed ID: 17581983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.